FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701-2978 www.FULBRIGHT.COM

DAVID L. PARKER
PARTNER
DPARKER@FULBRIGHT.COM

DIRECT DIAL: TELEPHONE: FACSIMILE:

(512) 536-3055 (512) 474-5201 (512) 536-4598

May 3, 2010

Commissioner for Patents

Attention: Certificates of Correction Branch

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF ELECTRONIC TRANSMISSION
I hereby certify that this correst management by the delectronically filed with the United States Palent and Trademark Office via EKS-Wky kyr the date below:

May 3, 2010
Date
David L. Parker

RE: Request for Certificate of Correction

Patent No. 7,671,010 Dated: March 2, 2010

Application No. 10/530,168 Confirmation No.: 5612

Entitled: "COMPOSITIONS AND METHODS OF USE OF TARGETING PEPTIDES FOR DIAGNOSIS AND THERAPY OF HUMAN CANCER" – Wadih ARAP et al.

Our Ref.: UTSC:857US

Commissioner:

Attached is form PTO-1050. Errors of a minor nature are thereon corrected. The errors are due to Patent Office oversight. A Certificate of Correction is requested under 35 U.S.C. § 254.

It is believed that no fees under 37 C.F.R. §§ 1.16 to 1.21 are occasioned by the filing of this paper; however, should the Commissioner determine otherwise, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/UTSC:857US.

David L. Parker

DLP/jst Attachment INVENTOR(S) :

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. 7,671,010

DATED March 2, 2010 Wadih ARAP et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In claim 17, column 151, line 4, delete "polysuiphate" and insert --polysulphate-therefor.

MAILING ADDRESS OF SENDER: David L. Parker FULBRIGHT & JAWORSKI L.L.P. 600 Congress Ave., Suite 2400 Austin, Texas 78701

PATENT NO. 7,671,010 No. of add'l. copies @ 50¢ per page